EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Chlamydia Infections - Pipeline Review, H1 2015

  • ID: 3266308
  • Report
  • April 2015
  • 76 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Abera Bioscience AB
  • Big DNA Ltd.
  • CEL-SCI Corporation
  • Genocea Biosciences, Inc.
  • Merck & Co., Inc.
  • Osel Inc.
  • MORE
Chlamydia Infections - Pipeline Review, H1 2015

Summary

This, ‘Chlamydia Infections - Pipeline Review, H1 2015’, provides an overview of the Chlamydia Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chlamydia Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abera Bioscience AB
  • Big DNA Ltd.
  • CEL-SCI Corporation
  • Genocea Biosciences, Inc.
  • Merck & Co., Inc.
  • Osel Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chlamydia Infections Overview
Therapeutics Development
Pipeline Products for Chlamydia Infections - Overview
Pipeline Products for Chlamydia Infections - Comparative Analysis
Chlamydia Infections - Therapeutics under Development by Companies
Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes
Chlamydia Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Chlamydia Infections - Products under Development by Companies
Chlamydia Infections - Products under Investigation by Universities/Institutes
Chlamydia Infections - Companies Involved in Therapeutics Development
Abera Bioscience AB
Adamis Pharmaceuticals Corporation
Big DNA Ltd.
CEL-SCI Corporation
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
Merck & Co., Inc.
Osel Inc.
Prokarium Ltd.
QureTech Bio AB
Chlamydia Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ab-03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acALY-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BDNA-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologic for Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-31G - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia trachomatis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Block Virulence for Chlamydia Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GEN-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Chlamydophila Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VNI-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlamydia Infections - Recent Pipeline Updates
Chlamydia Infections - Dormant Projects
Chlamydia Infections - Product Development Milestones
Featured News & Press Releases
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications
Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center’s Sexually Transmitted Infections Cooperative Research Center
Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chlamydia Infections, H1 2015
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2015
Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015
Chlamydia Infections - Pipeline by Big DNA Ltd., H1 2015
Chlamydia Infections - Pipeline by CEL-SCI Corporation, H1 2015
Chlamydia Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015
Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H1 2015
Chlamydia Infections - Pipeline by Merck & Co., Inc., H1 2015
Chlamydia Infections - Pipeline by Osel Inc., H1 2015
Chlamydia Infections - Pipeline by Prokarium Ltd., H1 2015
Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Chlamydia Infections Therapeutics - Recent Pipeline Updates, H1 2015
Chlamydia Infections - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Chlamydia Infections, H1 2015
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Abera Bioscience AB
Adamis Pharmaceuticals Corporation
Big DNA Ltd.
CEL-SCI Corporation
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
Merck & Co., Inc.
Osel Inc.
Prokarium Ltd.
QureTech Bio AB
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll